Orexin A (hypocretin 1) injected into hypothalamic paraventricular nucleus and spontaneous physical activity in rats
1 Endocrine Research Unit, Mayo Clinic and Mayo Foundation, Rochester 55905; 2 Veterans Affairs Medical Center and 3 Minnesota Obesity Center, Minneapolis 55417; and 4 Departments of Food Science and Nutrition, University of Minnesota, Saint Paul, Minnesota 55108 Submitted 24 March 2003 ; accepted i...
Gespeichert in:
Veröffentlicht in: | American journal of physiology: endocrinology and metabolism 2004-04, Vol.286 (4), p.E551-E559 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | 1 Endocrine Research Unit, Mayo Clinic and Mayo Foundation, Rochester 55905; 2 Veterans Affairs Medical Center and 3 Minnesota Obesity Center, Minneapolis 55417; and 4 Departments of Food Science and Nutrition, University of Minnesota, Saint Paul, Minnesota 55108
Submitted 24 March 2003
; accepted in final form 21 November 2003
In humans, nonexercise activity thermogenesis (NEAT) increases with positive energy balance. The mediator of the interaction between positive energy balance and physical activity is unknown. In this study, we address the hypothesis that orexin A acts in the hypothalamic paraventricular nucleus (PVN) to increase nonfeeding-associated physical activity. PVN-cannulated rats were injected with either orexin A or vehicle during the light and dark cycle. Spontaneous physical activity (SPA) was measured using arrays of infrared activity sensors and night vision videotaped recording (VTR). O 2 consumption and CO 2 production were measured by indirect calorimetry. Feeding behavior was assessed by VTR. Regardless of the time point of injection, orexin A (1 nmol) was associated with dramatic increases in SPA for 2 h after injection (orexin A: 6.27 ± 1.95 x 10 3 beam break count, n = 24; vehicle: 1.85 ± 1.13 x 10 3 , n = 38). This increase in SPA was accompanied by compatible increase in O 2 consumption. Duration of feeding was increased only when orexin A was injected in the early light phase and accounted for only 3.5 ± 2.5% of the increased physical activity. In a dose-response experiment, increases in SPA were correlated with dose of orexin A linearly up to 2 nmol. PVN injections of orexin receptor antagonist SB-334867 were associated with decreases in SPA and attenuated the effects of PVN-injected orexin A. Thus orexin A can act in PVN to increase nonfeeding-associated physical activity, suggesting that this neuropeptide might be a mediator of NEAT.
energy expenditure; hypothalamus; obesity; nonexercise activity thermogenesis
Address for reprint requests and other correspondence: J. A. Levine, Endocrine Research Unit, Joseph 5-194, Mayo Clinic Rochester, 200 First St. SW, Rochester, MN 55905 (E-mail: levine.james{at}mayo.edu ). |
---|---|
ISSN: | 0193-1849 1522-1555 |
DOI: | 10.1152/ajpendo.00126.2003 |